Deep dives, evidence grades, and clinical tools, all in one place.
Practice Signal
Anticoagulation Reversal & AF Stroke Prevention
Cardiology6 sources · Updated Jul 17, 2026
This review helps pharmacists reconcile the withdrawal of andexanet alfa, drug-specific reversal choices, and the evolving role of left atrial appendage closure in atrial fibrillation stroke prevention.
Bottom Line
In atrial fibrillation, the anticoagulation risk-benefit calculus now hinges on drug-specific reversal (idarucizumab for dabigatran, off-label four-factor prothrombin complex concentrate as the pragmatic default for factor Xa inhibitors after andexanet's withdrawal) and on left atrial appendage closure as a bleeding-sparing but not stroke-superior alternative in selected patients.
0.55
HR, non-procedural bleeding, LAAC
10.3% vs 5.6%
thromboembolic events, andexanet vs usual care
100%
median dabigatran reversal, idarucizumab
82%
andexanet hemostatic efficacy, ANNEXA-4
State of Play
Direct oral anticoagulants (DOACs) remain first-line for atrial fibrillation (AF) stroke prevention, cutting intracranial hemorrhage (ICH) roughly 50% versus vitamin K antagonists (VKAs) and lowering annual major bleeding from about 3% to 2%. Reversal strategy is now drug-specific, and left atrial appendage closure (LAAC) has moved from last-resort to a defensible shared-decision alternative in selected patients. Bleeding management still rests on largely low-certainty evidence, with clinical hemostasis rather than laboratory reversal driving decisions.
🔒
Full Analysis: Subscribers Only
The complete evidence synthesis, practice recommendations, and open questions.
What Changed
How It Fits the Guidelines
Effect chart & evidence comparison
Evidence at a Glance
Practice Considerations
Open Questions
Want the full review?
Subscribe to PharmD Signal for the complete evidence synthesis and practice recommendations on every topic, plus every deep analysis we publish.
Each Practice Signal is built from our published deep analyses and checked for clinical accuracy before it goes live.
Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.